Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Coty shares slid ~7.7% to $2.80 pre-market after reporting mixed Q4 results: quarterly loss of $-0.02/share (vs. consensus loss of -$0.01) and revenue of $1.27B (up 6.25% vs. $1.19B estimate). The company also guided Q1 adjusted EPS below estimates and flagged the Gucci Beauty license exit, implying a step-down in FY28 sales and profit. More broadly, several other pre-market movers declined (e.g., Moderna -12.4%, Wolfspeed -12%), consistent with a risk-cautious tape ahead of earnings updates.

Analysis

COTY is less a one-quarter miss story than a duration reset: the market is being asked to reprice a consumer brand portfolio with a visible FY28 earnings hole and weaker negotiating leverage on future licenses. That usually compresses the multiple before the P&L impact shows up, because investors anchor on the loss of optionality rather than current-year beats. If management cannot replace the departing license with higher-velocity owned brands, the spillover is margin quality deterioration and lower capital efficiency, not just lower revenue.

The second-order winner is not necessarily another prestige beauty name, but any competitor with cleaner brand ownership and less license dependence; that favors names like IPAR on relative quality grounds and keeps pressure on EL if category sentiment bleeds wider. Retailers may also use the transition to renegotiate shelf terms across the fragrance/beauty aisle, which can delay any simple "share shift" bull case and raise promo intensity over the next 1-2 quarters.

The current move looks tradable only if the street is still modeling the long-dated license loss as back-end noise. The contrarian risk is that the exit is already a known 2028 event, so if first-quarter guidance proves conservatively set and sell-through holds, the stock could mean-revert sharply from oversold levels. Falsification is straightforward: stabilization in next-quarter EPS/margin guide or evidence of successful brand replacement would undermine a short thesis; absent that, the path of least resistance is lower over the next 1-3 months.

MRNA is a separate setup: after a huge prior-day rerating, the premarket dip is more likely a post-binary digestion than a fresh fundamental signal, so chasing weakness is lower quality than waiting for the first pullback on confirmed volume. The rest of the tape looks like routine earnings mean reversion rather than a durable factor change.

Key Decisions for Investors

• Short COTY on any intraday bounce, targeting a 1-3 month repricing lower as the FY28 license overhang gets discounted; stop if management raises margin guidance or the stock reclaims the pre-event gap on volume.
• Pair trade: long IPAR / short COTY to express cleaner brand economics versus license-exit risk; this is a relative-value trade, not a broad beauty macro call.
• Avoid chasing MRNA after the prior-day gap higher; wait for a pullback and stabilization because the near-term risk is headline fade rather than a straight-line continuation.
• Set an alert for the next COTY earnings call and first-quarter sell-through data; if management can offset the license step-down with owned-brand growth, cover shorts quickly.